Jochem van der Voort van Zyp

Associate Professor - medical

Strategic program(s):

Contact

jvoortva@umcutrecht.nl

Pure profile

Research groups

Prostate cancer, MRI-guided radiotherapy

Research aim

The goal of MR-guided radiotherapy is further improve oncological outcome and reduce treatment related toxicity.

Go to group

Recent publications

All publications

How to focal boost in prostate cancer radiotherapy T Willigenburg, C Draulans, F J Pos, T M Seibert, I Syndikus, A Henry, A Mitchell, M Buijs, B A Jereczek-Fossa, S K B Spohn, T Pommer, B R Pieters, A C Tree, J R N van der Voort van Zyp
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2026, vol. 221

Diffusion weighted MRI-based hypoxic fraction as a prognostic factor in the FLAME trial prostate cancer cohort Karolína Menne Guricová, Petra J. van Houdt, Mar Fernandez Salamanca, Ivo G. Schoots, Georgios Agrotis, Cédric Draulans, Karin Haustermans, Robert J. Smeenk, Martina Kunze-Busch, Hans C.J. de Boer, Jochem R.N. van der Voort van Zyp, Floris J. Pos, Uulke A. van der Heide
Radiotherapy and Oncology, 2026, vol. 220

Learning from every patient Maarten J Kamphuis, Irene C van der Schaaf, Roxanne Gal, Joanne M van der Velden, J P Maarten Burbach, Nicolien Kasperts, Jochem R N van der Voort van Zyp, Joost J C Verhoeff, Danny A Young-Afat, Martijn P W Intven, Sofie A M Gernaat, Frederieke H van der Baan, Geraldine R Vink, Miriam Koopman, Faye J Raaijmakers, Fia Cialdella, Tariq A Lalmahomed, Jasmijn M Westerhoff, Renée Hovenier, Eline H Huele, Frederik R Teunissen, Dieuwke R Mink van der Molen, Sophie R de Mol van Otterloo, Merle Hattink, Mathijs L Tomassen, Lois A Daamen, Helena M Verkooijen
Journal of Clinical Epidemiology, 2026, vol. 195

Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? R L Westley, L A Daamen, F R Teunissen, D Vesprini, A Choudhury, F J Pos, H M Verkooijen, C D Fuller, S Choi, W A Hall, J R N van der Voort van Zyp, J P Christodouleas, A C Tree
Clinical Oncology, 2026, vol. 53

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL) Timo F.W. Soeterik, Marcin Miszczyk, Max Peters, Mateusz Bilski, Giulio Francolini, Pietro Garlatti, Luca Nicosia, Filippo Alongi, Maris Mezeckis, Justyna Kociolek, Carlo Greco, Tomasz Techmański, Eline H. Huele, Frederik R. Teunissen, Paulien G. Westhoff, Wessel Vis, Marie A.D. Haverkort, Jochem R.N. van der Voort van Zyp, Martijn P.W. Intven, Joanne M. van der Velden, Shahrokh F. Shariat, Wietse S.C. Eppinga
The Lancet Oncology, 2026, vol. 27, p.383-392

Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer Niven Mehra, Daniela E. Oprea-Lager, Addy C.M. van de Luijtgaarden, Jochem R.N. van der Voort van Zyp, Shafak Aluwini, Herman J. Stoevelaar, Roderick C.N. van den Bergh,
European Urology Open Science, 2026, vol. 85, p.126-129